Harvard Bioscience earnings missed by $0.03, revenue fell short of estimates

Investing.com - Harvard Bioscience (NASDAQ: HBIO) reported first quarter EPS of $0.020, $0.03 worse than the analyst estimate of $0.050. Revenue for the quarter came in at $24.5M versus the consensus estimate of $28M.

Harvard Bioscience's stock price closed at $3.92. It is down -16.060% in the last 3 months and down -33.780% in the last 12 months.

Harvard Bioscience saw 0 positive EPS revisions and 1 negative EPS revisions in the last 90 days. See Harvard Bioscience's stock price’s past reactions to earnings here .

According to good performance ".

Check out Harvard Bioscience's recent earnings performance, and Harvard Bioscience's financials here .

Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar

_newTouch_app_install_inline_banner_title

_newTouch_app_install_inline_banner_text

_newTouch_app_install_inline_banner_button